Mary Kerr

Prior to joining Advent in 2015, Mary held a range of senior leadership roles during her 20 years at GSK, most recently as Senior Vice President and Global Franchise leader for the Immuno-inflammation and Infectious Diseases franchise. She has spent the majority of her career on the R&D Commercial interface in global strategy and regional operational roles, predominantly in the speciality and orphan space.

She was a founding member of the Executive team of ViiV Healthcare (the independent, HIV company that combines the HIV expertise of GSK, Pfizer Inc. and Shionogi) where she led, revitalised and grew the business in Europe. Mary also established and built the European Critical Disease Business in GSK. Earlier in her career she held a range of diverse roles: Head of European Market Development and Global Head of Neurosciences Product Strategy at SmithKline Beecham and VP Pharmacogenetics and Diagnostics at GSK.

She gained a PhD in Pharmacology at the University of Bradford, did post doctoral research at the Michigan Cancer Foundation, Detroit and has an MBA from the University of Kingston.

Mary is the full time CEO of NeRRe Therapeutics, an Advent portfolio company.